Form 4: Genelux Corp Executive Yu Yong Reports Stock Transactions
SEC Form 4 Filing
VP of Clinical Trial Operations at Genelux Corp, Yu Yong, reports acquisition and disposal of common stock and restricted stock units.
Summary
- Yu Yong, VP of Clinical Trial Operations at Genelux Corp, filed a Form 4 detailing changes in beneficial ownership.
- On February 19, 2024, Yu Yong acquired 3,661 shares of common stock at $0.
- On March 14, 2024, Yu Yong acquired 11,557 shares of common stock at $0.
- On June 24, 2024, Yu Yong sold 6,849 shares of common stock at $2.12.
- Following these transactions, Yu Yong beneficially owns 10,869 shares of common stock.
- The sales were to cover estimated taxes related to the vesting of restricted stock units (RSUs).
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common for publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by an insider.
Key Dates
| Date | Description |
|---|---|
| 02/19/2024 | Acquisition of 3,661 shares of common stock. |
| 03/14/2024 | Acquisition of 11,557 shares of common stock. |
| 06/24/2024 | Sale of 6,849 shares of common stock at $2.12. |
| 07/08/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.